{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:59:24Z","timestamp":1792519164014,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-025-01058-2","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:02:07Z","timestamp":1762016527000},"page":"60-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial"],"prefix":"10.1038","volume":"7","author":[{"given":"Sijia","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4184-7844","authenticated-orcid":false,"given":"Fei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runye","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouyu","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0569-9001","authenticated-orcid":false,"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"1058_CR1","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jhep.2003.11.030","volume":"40","author":"YH Shaib","year":"2004","unstructured":"Shaib, Y. H., Davila, J. A., McGlynn, K. & El-Serag, H. B. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J. Hepatol. 40, 472\u2013477 (2004).","journal-title":"J. Hepatol."},{"key":"1058_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273\u20131281 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1058_CR3","doi-asserted-by":"crossref","unstructured":"Oh, D. Y., et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1, EVIDoa2200015 (2022).","DOI":"10.1056\/EVIDoa2200015"},{"key":"1058_CR4","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1853\u20131865 (2023).","journal-title":"Lancet"},{"key":"1058_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle, J. W., Kelley, R. K., Nervi, B., Oh, D. Y. & Zhu, A. X. Biliary tract cancer. Lancet 397, 428\u2013444 (2021).","journal-title":"Lancet"},{"key":"1058_CR6","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","volume":"25","author":"A Lamarca","year":"2014","unstructured":"Lamarca, A., Hubner, R. A., David Ryder, W. & Valle, J. W. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann. Oncol. 25, 2328\u20132338 (2014).","journal-title":"Ann. Oncol."},{"key":"1058_CR7","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery, M. A. et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin. Cancer Res. 24, 4154\u20134161 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1058_CR8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele, M. F. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 35, 588\u2013606 (2024).","journal-title":"Ann. Oncol."},{"key":"1058_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","volume":"40","author":"L Dong","year":"2022","unstructured":"Dong, L. et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell 40, 70\u201387 (2022).","journal-title":"Cancer Cell"},{"key":"1058_CR10","doi-asserted-by":"crossref","unstructured":"Lamarca, A. et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 22, 690\u2013701 (2021).","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"1058_CR11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","volume":"6","author":"RD Kim","year":"2020","unstructured":"Kim, R. D. et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 6, 888\u2013894 (2020).","journal-title":"JAMA Oncol."},{"key":"1058_CR12","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1016\/j.jvir.2009.12.403","volume":"21","author":"JP Erinjeri","year":"2010","unstructured":"Erinjeri, J. P. & Clark, T. W. Cryoablation: mechanism of action and devices. J. Vasc. Interv. Radiol. 21, S187\u2013S191 (2010).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"1058_CR13","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.juro.2012.06.014","volume":"188","author":"JL Chin","year":"2012","unstructured":"Chin, J. L., Al-Zahrani, A. A., Autran-Gomez, A. M., Williams, A. K. & Bauman, G. Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c\u2013T3b). J. Urol. 188, 1170\u20131175 (2012).","journal-title":"J. Urol."},{"key":"1058_CR14","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/hep.27548","volume":"61","author":"C Wang","year":"2015","unstructured":"Wang, C. et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology 61, 1579\u20131590 (2015).","journal-title":"Hepatology"},{"key":"1058_CR15","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1016\/S1470-2045(23)00615-0","volume":"25","author":"M Toi","year":"2024","unstructured":"Toi, M. et al. Non-surgical ablation for breast cancer: an emerging therapeutic option. Lancet Oncol. 25, e114\u2013e125 (2024).","journal-title":"Lancet Oncol."},{"key":"1058_CR16","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00262-020-02566-z","volume":"69","author":"L Shen","year":"2020","unstructured":"Shen, L. et al. Cryoablation combined with transarterial infusion of pembrolizumab (CATAP) for liver metastases of melanoma: an ambispective, proof-of-concept cohort study. Cancer Immunol. Immunother. 69, 1713\u20131724 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"1058_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.copbio.2020.01.006","volume":"65","author":"C Yakkala","year":"2020","unstructured":"Yakkala, C., Denys, A., Kandalaft, L. & Duran, R. Cryoablation and immunotherapy of cancer. Curr. Opin. Biotechnol. 65, 60\u201364 (2020).","journal-title":"Curr. Opin. Biotechnol."},{"key":"1058_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 293\u2013313 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1058_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03637-1","volume":"73","author":"L Shen","year":"2024","unstructured":"Shen, L., et al. Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy. Cancer Immunol. Immunother. 73, 68 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"1058_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1158\/0008-5472.CAN-11-1782","volume":"72","author":"R Waitz","year":"2012","unstructured":"Waitz, R. et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 72, 430\u2013439 (2012).","journal-title":"Cancer Res."},{"key":"1058_CR21","doi-asserted-by":"publisher","first-page":"544","DOI":"10.4161\/onci.19442","volume":"1","author":"R Waitz","year":"2012","unstructured":"Waitz, R., Fass\u00f2, M. & Allison, J. P. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. Oncoimmunology 1, 544\u2013546 (2012).","journal-title":"Oncoimmunology"},{"key":"1058_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26415-4","volume":"12","author":"MT Campbell","year":"2021","unstructured":"Campbell, M. T. et al. Pilot study of tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat. Commun. 12, 6375 (2021).","journal-title":"Nat. Commun."},{"key":"1058_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51722-x","volume":"15","author":"MJ Mooradian","year":"2024","unstructured":"Mooradian, M. J. et al. Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial. Nat. Commun. 15, 7357 (2024).","journal-title":"Nat. Commun."},{"key":"1058_CR24","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/sj.bjc.6603341","volume":"95","author":"MH den Brok","year":"2006","unstructured":"den Brok, M. H. et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br. J. Cancer 95, 896\u2013905 (2006).","journal-title":"Br. J. Cancer"},{"key":"1058_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41391-018-0035-z","volume":"21","author":"B Benzon","year":"2018","unstructured":"Benzon, B. et al. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. Prostate Cancer Prostatic Dis. 21, 126\u2013136 (2018).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1058_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006608","volume":"11","author":"M Alshebremi","year":"2023","unstructured":"Alshebremi, M. et al. Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation. J. Immunother. Cancer 11, e006608 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1058_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008386","volume":"12","author":"C Gu","year":"2024","unstructured":"Gu, C. et al. Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer. J. Immunother. Cancer 12, e008386 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1058_CR28","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.232365","volume":"310","author":"A Shewarega","year":"2024","unstructured":"Shewarega, A. et al. Effect of incomplete cryoablation and matrix metalloproteinase inhibition on intratumoral CD8+ T-cell infiltration in murine hepatocellular carcinoma. Radiology 310, e232365 (2024).","journal-title":"Radiology"},{"key":"1058_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"MS Lee","year":"2020","unstructured":"Lee, M. S. et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 21, 808\u2013820 (2020).","journal-title":"Lancet Oncol."},{"key":"1058_CR30","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","volume":"22","author":"PR Galle","year":"2021","unstructured":"Galle, P. R. et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 991\u20131001 (2021).","journal-title":"Lancet Oncol."},{"key":"1058_CR31","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","volume":"42","author":"L Cords","year":"2024","unstructured":"Cords, L. et al. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell 42, 396\u2013412 (2024).","journal-title":"Cancer Cell"},{"key":"1058_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9670","volume":"9","author":"M Schmittnaegel","year":"2017","unstructured":"Schmittnaegel, M. et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci. Transl. Med. 9, eaak9670 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1058_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2019.12.001","volume":"37","author":"J Goveia","year":"2020","unstructured":"Goveia, J. et al. An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates. Cancer Cell 37, 21\u201336 (2020).","journal-title":"Cancer Cell"},{"key":"1058_CR34","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.ccell.2022.11.002","volume":"40","author":"Y Hua","year":"2022","unstructured":"Hua, Y. et al. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1(+) T lymphocyte niches through a feed-forward loop. Cancer Cell 40, 1600\u20131618 (2022).","journal-title":"Cancer Cell"},{"key":"1058_CR35","doi-asserted-by":"publisher","first-page":"102410","DOI":"10.1016\/j.coi.2023.102410","volume":"86","author":"ZM Chua","year":"2024","unstructured":"Chua, Z. M., Tajebe, F., Abuwarwar, M. & Fletcher, A. L. Differential induction of T-cell tolerance by tumour fibroblast subsets. Curr. Opin. Immunol. 86, 102410 (2024).","journal-title":"Curr. Opin. Immunol."},{"key":"1058_CR36","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","volume":"10","author":"Y Kieffer","year":"2020","unstructured":"Kieffer, Y. et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 10, 1330\u20131351 (2020).","journal-title":"Cancer Discov."},{"key":"1058_CR37","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul, S. A. et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int. J. Cancer 147, 2190\u20132198 (2020).","journal-title":"Int. J. Cancer"},{"key":"1058_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07365-4","volume":"20","author":"M Ueno","year":"2020","unstructured":"Ueno, M. et al. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer 20, 1105 (2020).","journal-title":"BMC Cancer"},{"key":"1058_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103919","volume":"9","author":"M Ueno","year":"2024","unstructured":"Ueno, M. et al. Phase I\/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808\/NCCH1817, SNIPE). ESMO Open 9, 103919 (2024).","journal-title":"ESMO Open"},{"key":"1058_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.785535","volume":"12","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Lenvatinib beyond first-line therapy in patients with advanced biliary tract carcinoma. Front. Oncol. 12, 785535 (2022).","journal-title":"Front. Oncol."},{"key":"1058_CR41","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.soc.2013.10.008","volume":"23","author":"A Amini","year":"2014","unstructured":"Amini, A. & Gamblin, T. C. Palliation: treating patients with inoperable biliary tract and primary liver tumors. Surg. Oncol. Clin. N. Am. 23, 383\u2013397 (2014).","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"1058_CR42","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41379-020-00656-y","volume":"34","author":"N Guedj","year":"2021","unstructured":"Guedj, N. et al. Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinoma. Mod. Pathol. 34, 408\u2013416 (2021).","journal-title":"Mod. Pathol."},{"key":"1058_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz, K. F., Altman, D. G. & Moher, D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Brit. Med. J. 340, c332 (2010).","journal-title":"Brit. Med. J."},{"key":"1058_CR44","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"1058_CR45","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nmeth.4150","volume":"14","author":"X Qiu","year":"2017","unstructured":"Qiu, X. et al. Single-cell mRNA quantification and differential analysis with Census. Nat. Methods 14, 309\u2013315 (2017).","journal-title":"Nat. Methods"},{"key":"1058_CR46","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41587-020-0591-3","volume":"38","author":"V Bergen","year":"2020","unstructured":"Bergen, V., Lange, M., Peidli, S., Wolf, F. A. & Theis, F. J. Generalizing RNA velocity to transient cell states through dynamical modeling. Nat. Biotechnol. 38, 1408\u20131414 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1058_CR47","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41586-018-0414-6","volume":"560","author":"G La Manno","year":"2018","unstructured":"La Manno, G. et al. RNA velocity of single cells. Nature 560, 494\u2013498 (2018).","journal-title":"Nature"},{"key":"1058_CR48","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).","journal-title":"Nat. Commun."},{"key":"1058_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41592-019-0667-5","volume":"17","author":"R Browaeys","year":"2020","unstructured":"Browaeys, R., Saelens, W. & Saeys, Y. NicheNet: modeling intercellular communication by linking ligands to target genes. Nat. Methods 17, 159\u2013162 (2020).","journal-title":"Nat. Methods"},{"key":"1058_CR50","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268\u2013272 (2018).","journal-title":"Nature"},{"key":"1058_CR51","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"1058_CR52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357\u2013360 (2015).","journal-title":"Nat. Methods"},{"key":"1058_CR53","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"1058_CR54","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/PO.18.00414","volume":"4","author":"J Cao","year":"2020","unstructured":"Cao, J. et al. Intrahepatic cholangiocarcinoma: genomic heterogeneity between eastern and western patients. JCO Precis. Oncol 4, 557\u2013569 (2020).","journal-title":"JCO Precis. Oncol"},{"key":"1058_CR55","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","volume":"30","author":"B Niu","year":"2014","unstructured":"Niu, B. et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 30, 1015\u20131016 (2014).","journal-title":"Bioinformatics"},{"key":"1058_CR56","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert, C. et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28, 105\u2013113 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1058_CR57","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi, S. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 31, 860\u2013867 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1058_CR58","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01058-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01058-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01058-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:02:26Z","timestamp":1769785346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01058-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-01058-2","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}